- Title
- Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study
- Creators
- J. S. Ferriss (Author)J. J. Java (Author)M. A. Bookman (Author)G. F. Fleming (Author)Bradley J. Monk (Author) - Creighton UniversityJ. LWalker (Author)H. D. Homesley (Author)J. Fowler (Author)B. E. Greer (Author)M. P. Boente (Author)R. A. Burger (Author)
- Additional links
- http://doi.org/10.1016/j.ygyno.2015.07.103
- Publication Details
- Gynecologic Oncology, Vol.139(1), pp.17-22
- Publisher
- . Published by Elsevier Inc
- Number of pages
- 17-22
- Identifiers
- 991005932288002656
- Academic Unit
- School of Medicine; Obstetrics & Gynecology; General Medicine
- Language
- English
- Resource Type
- Journal article
Journal article
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study
Gynecologic Oncology, Vol.139(1), pp.17-22
07/26/2015
PMID: 26216729
Metrics
5 Record Views